Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Analgesics

Therapeutic area intelligence for Analgesics with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
0
Companies
1

Companies

Aurobindo Pharma →

Assets

Aurobindo →
FDA →
NCCIH →
Tylenol →

Recent signals(5)

StrategyJuly 25, 2026

FDA Approves First Nonprescription Acetaminophen and Naproxen Combination for Pain Relief

The FDA has approved Tylenol with Naproxen, a fixed-dose combination for 12-hour pain relief.

ClinicalJuly 12, 2026

Study on Methocarbamol for Pain Management in Hernia Repair

A clinical trial is underway to evaluate methocarbamol as a pain management option for hernia repair compared to standard opioid treatments.

RegulatoryJune 28, 2026

FDA Approval Status Update for Acetaminophen and Codeine Phosphate

The FDA has granted an AP status for the ANDA040419 application submitted by SPECGX LLC for Acetaminophen and Codeine Phosphate.

ClinicalJune 23, 2026

Pilot Study on Pain Medicines Pregabalin and Naproxen in Healthy Adults

A pilot study is testing the analgesic effects of pregabalin and naproxen in healthy adults using controlled pain tests.

RegulatoryJune 23, 2026

Aurobindo Pharma's ANDA218359 for Acetaminophen and Ibuprofen Receives AP Status

Aurobindo Pharma's ANDA218359 for a combination of acetaminophen and ibuprofen has received an Abbreviated Approval (AP) status from the FDA.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.